Outlook Therapeutics (OTLK) to Release Quarterly Earnings on Wednesday

Outlook Therapeutics (NASDAQ:OTLK) will announce its earnings results before the market opens on Wednesday, August 14th. Analysts expect the company to announce earnings of ($1.06) per share for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

Outlook Therapeutics (NASDAQ:OTLK) last announced its quarterly earnings data on Wednesday, May 15th. The company reported ($1.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.67). On average, analysts expect Outlook Therapeutics to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Outlook Therapeutics Trading Up 2.3 %

OTLK opened at $7.51 on Tuesday. Outlook Therapeutics has a 1-year low of $4.00 and a 1-year high of $32.00. The stock’s fifty day simple moving average is $7.63 and its 200 day simple moving average is $8.08. The stock has a market cap of $175.78 million, a PE ratio of -0.66 and a beta of 0.71.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of Outlook Therapeutics in a research note on Friday, May 17th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, Outlook Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $46.43.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.